Research programme: E2F-targeting anticancer therapeutics - TopoTarget

Drug Profile

Research programme: E2F-targeting anticancer therapeutics - TopoTarget

Alternative Names: E2F research programme - TopoTarget; E2F-targeting anticancer therapeutics research programme - TopoTarget

Latest Information Update: 10 Jul 2009

Price : $50

At a glance

  • Originator TopoTarget
  • Class Small molecules
  • Mechanism of Action Genetic transcription inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 10 Jul 2009 Discontinued - Preclinical for Cancer in Denmark (unspecified route)
  • 10 Jul 2009 Discontinued - Preclinical for Cancer in United Kingdom (unspecified route)
  • 23 Jan 2004 This programme is available for licensing (http://www.topotarget.com)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top